|
2018 Conference Publication A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabineVan der Zwan, W., Wyld, D., Brabander, T., Teunissen, J., Kam, B., MacFarlane, D., Krenning, E., Kwekkeboom, D. and de Herder, W. (2018). A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7 - 9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2014 Conference Publication Success with Lutetium-177 DOTATATE therapy in Cushing's syndrome caused by functional pancreatic neuroendocrine tumor (pNET) with ectopic adrenocorticotropic hormone (ACTH) secretion refractory to concomitant everolimus, pasireotide and metyraponeChan, B. A., Wyld, D., Burge, M., Cuneo, R., Macfarlane, D. and Lee, K. (2014). Success with Lutetium-177 DOTATATE therapy in Cushing's syndrome caused by functional pancreatic neuroendocrine tumor (pNET) with ectopic adrenocorticotropic hormone (ACTH) secretion refractory to concomitant everolimus, pasireotide and metyrapone. 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, 5 - 7 March 2014. Basel, Switzerland: S. Karger AG. |
|
2014 Conference Publication Novel succinate dehydrogenase subunit B intronic mutation in an Australian kindred with variable clinical and imaging phenotype necessitating different treatment modalities including 131-I MIBG and 177-Lutetium DOTATATELee, K., Conway, L., Burge, M., Wyld, D. and Macfarlane, D. (2014). Novel succinate dehydrogenase subunit B intronic mutation in an Australian kindred with variable clinical and imaging phenotype necessitating different treatment modalities including 131-I MIBG and 177-Lutetium DOTATATE. 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 5 - 7 March 2014. Basel, Switzerland: S. Karger AG. |
|
2013 Conference Publication Breath-hold low dose CT immediately following PET/CT enables good quality virtual bronchoscopy prior to EBUS guide sheath biopsyFielding, David, Bashirzadeh, Farzad, Smith, Jye, Garcia, Peter, Frecker, Sue and Macfarlane, David (2013). Breath-hold low dose CT immediately following PET/CT enables good quality virtual bronchoscopy prior to EBUS guide sheath biopsy. New York, NY, United States: Elsevier. |
|
2012 Conference Publication Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's HospitalSharma, A., Burge, M., MacFarlane, D., McDade, H., Kemp, S. and Wyld, D. (2012). Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting , Brisbane, QLD, Australia, 8 – 10 August 2012. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2011 Conference Publication Radiopeptide lite - an automated radiopeptide labelling system using disposable cassettesCombs, M., Stimson, D., Yordanov, A. and Macfarlane, D. (2011). Radiopeptide lite - an automated radiopeptide labelling system using disposable cassettes. 41st Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine, Darwin, NT, Australia, 14 ‐ 18 July 2011. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. |
|
2011 Conference Publication Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective studyBurge, M., Houston, K. E., Francesconi, A., O'Rourke, N., Lee, J., Macfarlane, D., Wyld, D., Hopkins, G., Finch, R. and Nathanson, L. (2011). Does the addition of FDG-PET to the standard pre-operative work up of pancreatic cancer change management - a prospective study. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011. Elsevier: Oxford, United Kingdom. |
|
2011 Conference Publication (68)Ga-dotatate: synthesis, automation, and quality controlStimson, D., Macfarlane, D., Combs, M. and Yordanov, A. (2011). (68)Ga-dotatate: synthesis, automation, and quality control. 41st Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine, Darwin, NT, Australia, 14 ‐ 18 July 2011. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. |
|
2010 Conference Publication Improved delineation of brain tumour margins using whole-brain track-density mappingRose, S., Crozier, S., Bourgeat, P., Dowson, N., Salvado, O., Raniga, P., Pannek, K., Coulthard, A., Fay, M., Thomas, P. and MacFarlane, D. (2010). Improved delineation of brain tumour margins using whole-brain track-density mapping. ISMRM-ESMRMB Joint Annual Meeting 2010: Clinical Needs and Technological Solutions, Stockholm, Sweden, 1-7 May 2010. New York, USA: International Society of Magnetic Resonance in Medicine. |
|
2010 Conference Publication Joint factor and kinetic analysis of dynamic FDOPA PET scans of brain cancer patientsDowson, N., Bourgeat, P., Rose, S., Daglish, M., Smith, J., Fay, M., Coulthard A., Winter, C., MacFarlane, D., Thomas, P., Crozier, S. and Salvado, O. (2010). Joint factor and kinetic analysis of dynamic FDOPA PET scans of brain cancer patients. 13th International Conference on Medical Image Computing and Computer-Assisted Intervention, MICCAI 2010, Beijing, China, 20 - 24 September 2010. Heidelberg, Germany: Springer. doi: 10.1007/978-3-642-15745-5_23 |
|
2001 Conference Publication Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.Durrant, S., Irving, I., Mollee, P., Morton, A. J., Webb, M. and Macfarlane, D. (2001). Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.. 27th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, United Kingdom: Nature Publishing Group. |
|
1998 Conference Publication Iodine-131 anti-B1 antibody for B-cell lymphoma: An update on the Michigan phase I experienceWahl, RL, Zasadny, KR, MacFarlane, D, Francis, IR, Ross, CW, Estes, J, Fisher, S, Regan, D, Kroll, S and Kaminski, MS (1998). Iodine-131 anti-B1 antibody for B-cell lymphoma: An update on the Michigan phase I experience. Symposium on B1 Therapy in Non-Hodgkins Lymphoma - Dosimetry and Clinical Implications, San Antonio Texas, Jun 01, 1997. |
|
1997 Conference Publication Venoconstriction is impaired during volume unloading in chronic heart failureAtherton, J., Thomson, H. L., Macfarlane, D., Fong, W., Moore, T., Wright, K., Muehle, G., Fitzpatrick, L. and Frenneaux, M. (1997). Venoconstriction is impaired during volume unloading in chronic heart failure. 3rd International Congress of Nuclear Cardiology, Florence, Italy, April 1997. Journal of Nuclear Cardiology: Springer. doi: 10.1016/S1071-3581(97)91237-X |
